Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Mylan Inc. (MYL - Analyst Report) recently announced that it has launched its generic version of Abbott Laboratories’ (ABT - Analyst Report) Trilipix. The drug is approved as an adjunct to diet in combination with a statin to bring down the levels of triglyceride and increase high-density lipoprotein cholesterol.

Mylan launched the drug following approval from the US Food and Drug Administration of the abbreviated new drug application (ANDA) filed by the company seeking approval to market its generic version of Trilipix. Mylan’s generic unit has seen quite a few launches over the past few months. The segment is expected to continue performing well, thereby driving growth at Mylan.

In a separate development, Mylan was recently sued by UCB (UCBJF) The patent challenge follows the generic company's filing of an ANDA as it seeks to market its generic version of UCB’s Vimpat (lacosamide tablets, 50 mg, 100 mg, 150 mg and 200 mg).

Vimpat has been approved as an adjunctive therapy for treating patients, aged 17 years and above, suffering from partial-onset seizures with epilepsy. Apart from UCB Research Corporation Technologies, Inc., Harris FRC Corporation have also challenged Mylan’s ANDA.

Mylan believes it may be the first-to-file an ANDA for a generic version of Vimpat – if this is the case, the company would be entitled to 180 days of exclusivity on gaining approval from the US Food and Drug Administration (FDA) for its candidate. As per IMS Health data, Vimpat sales in the US were $338 million for the twelve months ended Mar 31, 2013.

Mylan, one of the largest players in the global generics market, has a presence in more than 140 countries. As of Jul 15, 2013, the company had 173 ANDAs pending FDA approval, representing $82.9 billion in annual sales. These include 35 first-to-file opportunities.

Mylan carries a Zacks Rank #3 (Hold). Actavis, Inc. (ACT - Analyst Report) appears to be more attractive in the generic space with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%